DDP-38003 triHCl is a novel, orally bioactive KDM1A/LSD1 inhibitor (antagonist) with IC50 of 84 nM.

Physicochemical Properties

Molecular Formula	C21H29CL3N4O
Molecular Weight	459.84
Related CAS #	DDP-38003 dihydrochloride;1831167-98-6
Appearance	Yellow to reddish brown solid powder
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	IC50: 84 nM (KDM1A/LSD1)[1]
ln Vitro	DDP-38003 suppresses KDM1A with an IC50 of 84 nM. DDP-38003 exhibits greater efficacy than its 1R, 2S counterpart in diminishing the colony forming capacity and promoting differentiation in THP-1 cells [1].
ln Vivo	In mice leukemia models, DDP-38003 shows in vivo efficacy following oral dosing, resulting in a 62% improvement in survival with evidence of KDM1A suppression. DDP-38003 has an 8-hour half-life. Treatment with DDP-38003 results in a significant dose-dependent increase in mouse survival. At doses of 11.25 and 22.50 mg/kg, respectively, there is a 35% and 62% increase in survival rate. An oral anticancer drug called DDP-38003 is possible[1].
References	[1]. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. J Med Chem. 2016 Feb 25;59(4):1501-17.

Solubility Data

Solubility (In Vitro)

DMSO :~100 mg/mL (~217.47 mM) H2O :~50 mg/mL (~108.73 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (5.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 50 mg/mL (108.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.1747 mL	10.8733 mL	21.7467 mL
	5 mM	0.4349 mL	2.1747 mL	4.3493 mL
	10 mM	0.2175 mL	1.0873 mL	2.1747 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.